US 12,103,931 B2
Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
Zhiwei Wang, Beijing (CN); Yunhang Guo, Beijing (CN); and Gongyin Shi, Beijing (CN)
Assigned to BeiGene Switzerland GmbH, Basel (CH)
Filed by BEIGENE SWITZERLAND GMBH, Basel (CH)
Filed on Nov. 3, 2023, as Appl. No. 18/386,777.
Application 17/901,951 is a division of application No. 17/858,827, filed on Jul. 6, 2022, granted, now 11,814,389.
Application 18/386,777 is a continuation of application No. 17/901,951, filed on Sep. 2, 2022, granted, now 11,851,437.
Application 17/858,827 is a continuation of application No. 17/146,855, filed on Jan. 12, 2021.
Application 17/146,855 is a continuation of application No. 16/325,447, granted, now 10,927,117, issued on Feb. 23, 2021, previously published as PCT/IB2017/054955, filed on Aug. 15, 2017.
Claims priority of application No. PCT/CN2016/095510 (WO), filed on Aug. 16, 2016.
Prior Publication US 2024/0092786 A1, Mar. 21, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 487/04 (2006.01); A61P 35/00 (2006.01); A61P 35/02 (2006.01); A61P 35/04 (2006.01)
CPC C07D 487/04 (2013.01) [A61P 35/02 (2018.01); A61P 35/04 (2018.01); C07B 2200/13 (2013.01)] 16 Claims
 
1. A chiral acid salt of Formula (Id):

OG Complex Work Unit Chemistry
wherein R1 is methyl, benzyl, 4-methoxybenzyl, or tert-butyloxycarbonyl; and
the chiral acid is L-malic acid, D-malic acid, L-mandelic acid, D-mandelic acid, L-camphorsulfonic acid, D-camphorsulfonic acid, L-tartaric acid, D-tartaric acid, L-DBTA, D-DBTA, L-DTTA, or D-DTTA.